OGI INVESTORS’ PRESENTATION |

OGI INVESTOR PRESENTATIONNASDAQ (OGI)TSX (OGI)

Cautionary StatementThis document is current as of April 27, 2020, except where otherwise stated. The information contained in thispresentation is provided by Organigram (“OGI” or the “Company”) for informational purposes only and does notconstitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of OGI or otherfinancial products. No part of this presentation shall form the basis or be relied upon in connection with anycontract, commitment or investment decisions in relation thereto. The information contained herein is notinvestment or financial product advice and is not intended to be used as the basis for making an investmentdecision. No securities commission or similar regulatory authority in Canada has reviewed this presentation.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness orcorrectness of the information, opinions and conclusions contained in this presentation. This presentation is notmeant to provide a complete or comprehensive analysis of OGI’s financial or business prospects. To themaximum extent permitted by law, none of OGI nor its directors, officers, employees or agents, nor any otherperson accepts any liability, including, without limitation, any liability arising out of fault or negligence, for anyloss arising from the use of the information contained in this presentation.

Certain of the information in this presentation contains certain “forward-looking information” withinthe meaning of applicable securities laws (“forward-looking information”). Forward-looking information, ingeneral, can be identified by words such as “outlook”, “objective”, “plan”, “expect”, “project”, “intend”,“believe”, “anticipate”, “estimate”, “continue”, “budget”, “schedule” or “forecast” and other similar words, orstatements that certain events or conditions “may”, “could”, “would’, “might” or “will” occur. Forward-lookinginformation is based on the opinions and estimates of management at the date the statements are made, andare subject to a variety of risks and uncertainties and other factors that could cause actual events or results todiffer materially from those anticipated in forward-looking information, including, among others, the impact,duration and magnitude of COVID-19, heightened uncertainty as a result of COVID-19; timelines for temporarylayoffs; changing market and consumer patters related to existing and new product forms; modifiedconstruction plans for phases 4c and 5; timing for launch of new product forms, actions of customers, suppliers,partners, distributors, competitors or regulatory authorities; factors impacting the future market of theCanadian cannabis market and the Company’s future economic performance, OGI’s crop yields, product liability,government regulation, legislative and regulatory developments (including in relation to cannabis from HealthCanada), OGI’s expansion plans, as well as those risk factors identified in OGI’s most recent MD&A, AIF andother disclosure documents available on SEDAR at www.sedar.com and www.sec.gov/edgar.shtml under OGI’sissuer profile. The information contained in this presentation should be considered in the context ofthe circumstances prevailing at the time and OGI undertakes no obligation to update forward-lookinginformation to reflect material developments which may occur after the date this presentation was prepared orif circumstances or management’s estimates or opinions should change except as required by law. The readeris cautioned not to place undue reliance on forward-looking statements.

The financial information in this document contains certain financial performance measures that are notdefined by and do not have any standardized meaning under IFRS and are used by management to assess thefinancial and operational performance of the Company. These include cost of cultivation, adjusted EBITDA andadjusted EBITDA.as a percentage of net revenue (adjusted EBITDA margin %). The Company believes that thesenon-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enableinvestors to evaluate the Company’s operating results, underlying performance and prospects in a similarmanner to the Company’s management. As there are no standardized methods of calculating these non-IFRSmeasures, the Company’s approach may differ from those used by other issuers, and accordingly, the use ofthese measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provideadditional information and should not be considered in isolation or as a substitute for measures of performanceprepared in accordance with IFRS. For further information regarding these non-IFRS measures, includingdefinitions, a quantitative reconciliation to the most directly comparable IFRS measure, see the final slides inthis presentation.

Readers are cautioned against comparing cost of cultivation per gram harvested with cost of sales for the sameperiod for at least two reasons. 1. Cost of sales includes packaging costs which “cost of cultivation” does not. 2.There is a delay between when product is harvested and when it is sold and cost of cultivation does not includeindirect production costs.

This presentation does not constitute an offer of shares for sale in the United States or to any person that is, oris acting for the account or benefit of, any U.S. person as defined in Regulation S under the United StatesSecurities Act of 1933, as amended (the “Securities Act”) (“U.S. Person”), or in any other jurisdiction in whichsuch an offer would be illegal. OGI’s shares have not been and will not be registered under the Securities Act.We seek safe harbour.

This document may not be reproduced, further distributed or published in whole or in part by any other person.This document may only be disseminated or transmitted into any jurisdiction in compliance with, and subject to,applicable securities laws. Readers are required to ensure their compliance with applicable securities laws.

2

3

Organigram at a Glance

• Leading licensed producer of premium quality product for Medical & Adult Recreational Markets

• Indoor facility in Moncton, NB with unique three-level cultivation technology and licensed production capacity of 89,000 kg/yr

• Sales to all 10 provinces

• Focused on continuous improvement, innovation and automation

4

Pre-rolls 7% & other

• On April 7, 2020, announced temporary layoff of ~45% of its workforce1 (or ~400 employees) primarily to help protect the health of employees

• Made lump sum payments to affected employees and is absorbing employee paid portion of health, dental & short-term disability premiums for all employees and expect a one-time charge of ~$0.6M

• Maintaining an experienced group of employees at Moncton facility with skills flexible enough to work on different production/packaging lines to fulfill anticipated demand

• Expect reductions to production/packaging capacity and plan to supplement with inventories on hand to meet anticipated demand and focus on leveraging automated, most efficient lines of production

Corporate Action Plan – COVID-19

1. These numbers are subject to change as additional employees elect to take a temporary layoff in response to COVID-19

5

Pre-rolls 7% & other

• Net revenue of $23.2 million compared to $26.9M in Q2 2019 and $25.2M in Q1 2020

• Adult-use recreational net revenue grew 16% to $15.0M from $12.9M in Q1 2020

• Ended the quarter with $41.2M in cash and short-term investments; estimated total capex to occupy Phase 4C and Phase 5 was ~$13M1 at quarter-end

• Shipped first Rec 2.0 products with Trailblazer Torch vape cartridges in December 2019, followed by Edison Feather ready-to-go distillate vape pens and Edison Bytes, cannabis-infused chocolates, in February 2020

• Expect Edison PAX ERA distillate cartridges, premium line of vape products, to launch in Q2 calendar 2020

• Subsequent to quarter-end, received licensing for remainder of Phase 5, which includes a dedicated edibles and derivatives facility

• Announced corporate action plan intended to protect the health of employees as well as maintain sufficient business continuity to meet anticipated demand during this period

Q2 Fiscal 2020 Highlights

1. Comprised of $2M to spend on Phase 4 (estimate to complete 4C as originally intended was $10M) and $11M estimated to complete Phase 5.

NET REVENUE GROSS MARGIN (GM)before FV CHANGES to BIO ASSETS & INVENTORIES SOLDQ2 2020 net revenue down from Q2 2019

primarily due to: the timing of large pipeline orders to fill supply shortages in Q2 2019; lower average net selling price in Q2 2020 from increased competition; and a Q2 2020 provision for returns and price adjustments largely related to cannabis oil and other slow-moving product. This was partially offset by the launch of Rec 2.0 products, and wholesale revenue in Q2 2020.

Q2 2020 GM down from Q2 2019 on lower net revenue and higher cost of sales primarily due to: higher post-harvest costs; inventory provisions and write-offs primarily related to legacy packaging; and higher costs associated with the launch of Rec 2.0 products

Q2 2020 negative adjusted EBITDA was largely impacted by lower gross margin before fair value adjustments and higher SG&A1 compared to Q2.

Higher SG&A largely due to increased staffing as well as sales and marketing efforts, including a significant brand marketing campaign and costs related to the launch of new Rec 2.0 products.

Q2 Fiscal 2020 Financial Results

37.1

1.0

8.8

24.826.9

12.4

1. Adjusted EBITDA is a non-IFRS measures with no standardized meaning under IFRS. See the Company’s Q1 2020 MD&A for definitions and a reconciliation to IFRS.

2. Sales & Marketing and General & Administrative excluding share-based compensation

3. Net income (loss) from continuing operations

6

26.9

23.2

Q2 2019 Q2 2020

($M)

16.0

7.4

60%

32%

Q2 2019 Q2 2020

($M and %)

Q2 2020 net loss of $6.8 million, or $(0.041) per share on a diluted basis, compared to Q2 2019 net loss of $6.4 million, or $(0.049) per share, largely due to higher SG&A expenses in Q2 2020 as described above

ADJUSTED EBITDA1 NET LOSS3

13.3

Q2 2019 Q2 2020

($M)

(1.1)(6.4) (6.8)

Q2 2019 Q2 2020

($M)

(1.0)19.9

FY-2018 FY-2019

($M)

NET REVENUE GROSS MARGINbefore FV CHANGES to BIO ASSETS & INVENTORIES

• 2019 net revenue grew over 6 times or 547% from 2018 on the legalization of adult-use recreational cannabis in Canada

• Gross margin before fair value changes to bio assets and inventory increased 575% to 47% from 2018

• 2019 positive adjusted EBITDA margin2 of 25% as a percentage of net revenue

• 2019 SG&A3 at 41% of net revenue

Fiscal 2019 Financial Results

37.1

1.0

8.8

24.826.9

12.4

1. Based on the Company’s analysis of available data including, but not limited to, market share data from select provinces and various public data

2. Adjusted EBITDA is a non-IFRS measures with no standardized meaning under IFRS. See Company’s Q4 2019 MD&A.

3. Sales & Marketing and General & Administrative excluding share-based compensation

4. From continuing operations

7

12.4

80.4

FY-2018 FY-2019

($M)

5.6

37.9

45%

47%

FY-2018 FY-2019

($M and %)

• 2019 net loss of $9.5M or $0.07 per share (fully diluted) largely due to fair value changes to bio assets and inventory

POSITIVE ADJUSTED

EBITDA2

NET INCOME (LOSS)4

Three Level Indoor Cultivation Technology

• 3 level growing optimizes

footprint

• Control critical facets

of environment with

state-of-the-art technology

and innovation

• Data driven decisions

8

Phase 4 Expansion of Moncton Campus

9

1 Target production capacity once licensed and fully operational; several factors can cause actual capacity and costs to differ from estimates. See “Risk Factors” in the Company’s Q2 2020 MD&A.

2 Estimated capital cost to complete Phase 4 with 4C was originally contemplated (for 113,000 kg/yr) was $10 million at the end of Q2 Fiscal 2020.

9

• Current licensed production capacity of 89,000kg/yr1, with all Phase 4A and Phase 4B rooms licensed

• Delayed completion of Phase 4C2 to:

• Prioritize and effectively manage cash flow; and

• Potentially use portions of Phase 4C space for other strategic purposes

• Estimated capital cost to complete Phase 4, such that 4C can be occupied and used for other potential purposes, was ~$2M2 at the end of Q2 Fiscal 2020

PHASES 4A & 4B COMPLETE

89,000 KG/YRCURRENT

LICENSED TARGET PRODUCTION CAPACITY

PHASES 4A & 4B

COMPLETE

• 56,000 square feet within existing Moncton Campus facility being refurbished and designed under EU GMP standards for:

• An edibles and derivative production facility; and

• Additional extraction capacity (CO2 and hydrocarbon)

• Fully licensed as of late March 2020

• Estimated capital cost to complete was ~$11M at end of Q2 Fiscal 2020, largely related to the installation of certain equipment in the edibles and extraction areas

• Funds will be expended at a slower pace to balance near-term priorities with respect to COVID-19

Phase 5 - Refurbishment for Edibles and Derivative Products

10 1 Several factors can cause actual capacity and costs to differ from estimates. See “Risk Factors” in the Company’s Q2 2020 MD&A.

11

Adult Recreational Branding Strategy

NOTE: Trailblazer Chocolate and Ankr not launched yet.

12

• New core strains being launched across the country –previously

highly successful limited time offers

• Limelight, ultra-sour sativa at 20-27% THC

• El Dorado, hybrid at 18-20% THC

• Trailer Park Buds (TPB) to be first large format value SKU (28g)

• TPB well-positioned in Value segment with higher quality product

versus current competition (mostly greenhouse in market) and

relatively lower cost of cultivation

• Expect to reach new consumers by seizing the emerging holistic

health opportunity with the launch of Ankr Organics products

anticipated to launch in Q3 calendar 2020 in 3.5g size

Expanding OGI Rec 1.0 Portfolio

El DoradoLimelight

13

Pre-rolls 7% & other

Well-positioned for Edibles and Derivatives

Exclusive agreement with TGS Global, LLC1, a

vertically integrated cannabis company which

owns and operates >300,000 sq ft of production

and processing facilities, as well as medicinal and

adult-use retail stores in Colorado, for consulting

services re: product processing and development

as well as market segmentation and trends

Immediate increased extraction capacity

from Valens GroWorks agreement and

Phase 5 refurbishment underway for

additional in-house extraction capacity

1. Formerly TGS International LLCNOTE: The Company has no equity or other financial interest in TGS, nor does it provide TGS with any products or services. The terms of the agreement provide for a royalty payment to TGS on products sold in Canada. Organigram has no investment or ownership in any entity in the United States nor does it provide any products or services to entities in the United States.

14

Well-positioned for Edibles and Derivatives

1. QUICK TAKE - Cannabis - Cowen's THC Tracker: U.S. Brands - Cowen and Company, March 29, 2019

*Tinctures & sublingual, topicals, and capsules.

Initial OGI focus on two largest segments based on US state sales data in the edibles and derivative market - vaporizer pens and edibles, including beverages, representing 23% and 13%, respectivelyof total US recreational cannabis state sales1

15

OGI Vaporizer Pen Portfolio• As planned, began shipping Trailblazer Torch vape cartridges in

December 2019

• Started shipping Edison + Feather ready-to-go distillate pens in

February 2020

• Selected as one of the Canadian partners for PAX ERA, the

premium closed loop vaporizer system created by PAX Labs, Inc.

• PAX Labs, Inc. - a leader in the design and development of premium

app-controlled vape technologies for cannabis

• Selected as exclusive Canadian supplier of Feather Company’s

industrial design-patented vaporizer hardware and technology

• Expect to launch PAX ERA distillate cartridges in Q2 calendar 2020

16

• ~$15M investment in high-speed, high-capacity, fully-automated production line that includes advanced engineering, robotics, high-speed labeling, automated carton packing

• OGI product development and production team has more than deep chocolate expertise

• Commissioning of the production line completed in January 2020

• Shipped first product in February 2020, Edison Bytes, truffles in milk and dark chocolate available in 2 with 5mg of THC each or 1 with 10mg

Premium Cannabis-infused Chocolates

Proprietary Nano-Emulsification TechnologyDissolvable Powder Product

• Proprietary nano-emulsion technology, developed by internal R&D team

• An expected initial absorption of cannabinoids in 10-15 minutes once ingested by adding to a liquid

• Anticipated stability to temperature variations, mechanical disturbance, salinity, pH and sweeteners as well as being shelf stable, water-compatible, and unflavoured

• Offers consumers a measured dose of cannabinoids to add to a beverage of their choice while also offering discretion, portability and shelf life of a dry powder

17 NOTE: Due to reduced workforce as a result of COVID-19, the Company can no longer provide guidance on the launch timing of the powdered beverage product

Award-winning Products and Brands

18

Won Top Product Award

in the High

THC Bottled Oil Category

for our medical product,

Rossignol

Runner-up for medical

High THC Bottled Oil

Banook and recognized in

7 other categories

Leafly Readers Choice Award Winners

19

Products from our Edison Cannabis Co. Brand have

been chosen as the best in Canada!

TOP CBD OILEDISON CBD

TOP THC OILEDISON SATIVA

TOP THC-DOMINANT FLOWER LA STRADA

TOP PRE-ROLLEL DORADO PRE-ROLL

Top Licensed Producer, #2The Edison Cannabis Co

Mentions: Top THC-Dominant Flower, #7 Rio Bravo

Top Pre-Roll, #4 Edison La Strada

Top THC-Dominant Flower, #8 Lola Montes

Top Balanced Oil, #3Edison 5:5

20

Biosynthetic Cluster A physically clustered group of two or more genes in a particular genome that together encode a biosynthetic pathway for the production of a specialized metabolite.

i1

2

3

INSERT BIOSYNTHETIC CLUSTER INTO DNA VECTOR

The process is conducted at a large scale, resulting in materials that can be further processed into purified cannabinoids

GENOME ENGINEERING OF HOST

DNA is inserted into the bacteria, where it provides

instructions to produce cannabinoid compounds(s).

How it works?

Biosynthesis can be used to produce cannabinoids that are biologically identical to those produced by the plant itself.

BIOSYNTHESISA proprietary cannabinoid

manufacturing system that can product rare

cannabinoids.

Investment in Disruptive Technology-Biosynthesis

• Investment in Hyasynth, a biotech company and leader in the field

of cannabinoid science and biosynthesis

• Hyasynth using a disruptive technology – biosynthesis - to

naturally produce cannabinoids without growing cannabis plants

• Process has the potential to create a scalable supply of pure

cannabinoids at a fraction of the cost of traditional cultivation

• Process begins by inserting genes into the yeast’s natural

metabolism causing the production of cannabinoid precursors by

the yeast

• Hyasynth has developed patent-pending enzymes that allow for

the production of CBG, CBD and THC from the precursor

molecules

21

1. The weighted average share price was calculated using the spot rate on the day of settlement

2. While the Company believes it will be successful in negotiating the amendment, there is no guarantee that it will obtain the amendment, or that the terms of the amendment will not impose more onerous obligations on the Company. Any such result could have a material adverse effect on the financial position, operations, business and prospects of the Company.

• Cash and short-term investments of $41M as at end of Q2 Fiscal 2020

• Obtained waiver for violation of fixed charge ratio covenant on term loan to waive compliance until May 30, 2020 and currently renegotiating credit facility agreement

• $30M remains undrawn on total term loan of $115M2 as of April 14, 2020 and a revolver of up to $25M2 to be drawn against specified receivables

• The at-the-market equity program (“ATM Program”) established in December 2019 completed as at end of Q2 2020

• Issued ~16.2M common shares for gross proceeds of ~$55.0M in Q2 2020 at weighted average price of $3.39 per common share1 and net proceeds of $52.9 million after agents’ commissions, regulatory, and legal fees

• To further strengthen the balance sheet, announced a new ATM Program April 22, 2020 to allow issuance of common shares for up to C$49M

• ATM net proceeds used and intend to continue to be used to fund capital projects, for general corporate purposes and to repay indebtedness

Liquidity and Capital

Executive Team

22

Ray GracewoodPaolo DeLuca Tim Emberg Helen Martin Cameron Bishop Matt Rogers

SVP, Marketing & Communications

• More than 15 years of SVP, Sales & Commercial Operations

• experience in the marketing industry with expertise building and developing brands.

• Prior to OGI, Ray was the Senior Director of Sales & Marketing for Moosehead Breweries Ltd.

Chief Strategy Officer

• More than 20 years of diversified financial business experience in senior financial, investor relations and accounting roles.

• Prior experience includes roles at West Face Capital, Meridian LNG, Potash Ridge, C.A. Bancorp and TD Securities.

SVP, Sales

• A seasoned, bilingual sales, marketing and market access and regulatory leader with proven experience in healthcare, over-the-counter and CPG organizations.

• Prior experience includes roles at Roche Canada, Jamieson Laboratories and Frito-Lay Canada.

Greg Engel

Chief Executive Officer

• Seasoned executive with 30 years of Canadian and international experience within the pharma, biotech, cannabis and CPG industries.

• Prior to OGI, Gregory was most recently the CEO of Tilray.

SVP, Strategic & Legal Affairs

• A seasoned legal professional with experience spanning private practice corporate and securities law.

• Prior to OGI, Helen served for four years as the COO of a TSX-listed issuer within the financial sector.

VP, Public Affairs & Stakeholder Relations

• A public affairs expert with over 20 years of experience in government affairs and stakeholder relations.

• Prior to OGI, Cameron led government affairs for Tilray and held various health policy and government relations roles outside of the cannabis industry.

VP, Operations

• As one of Organigram’s first employees from 2015, Matt has held various operational roles within the company.

• Matt brings continuous improvement, operational analytics and cost control experience from his prior roles at GanongBros., Canada’s oldest candy company.

Derrick West

Chief Financial Officer

• Served as the Chair of the Audit Committee of OGI's Board from December 2017 to February 2020 and more recently served as part of the Investment Committee.

• Prior to OGI, Derrick - a chartered accountant -served in various CFO and executive financial and accounting roles.

✓Producing high quality indoor cannabis at one of the lowest costs of cultivation1 among Canadian LPs

✓Strong execution, cost management culture reflected in operating and financial results with positive adjusted EBITDA1 reported in the last 5 out of 7 quarters

✓Positioned well in Rec 2.0 edibles and derivative market:

▪ Launched 2 of 3 vape products and cannabis-infused chocolates to date

▪ Nearing completion of dedicated edibles and derivative facility at Moncton Campus

✓ Invested in biosynthesis for potential future production of cannabinoids at a fraction of traditional cultivation costs

✓Modest expansionary capital expenditures remaining at $13M for Phase 4 and 5

✓Disciplined capital allocation focused on maximizing return on investment for shareholders

✓Attractive market valuation relative to Canadian LP peers

231. Cost of cultivation per gram and adjusted EBITDA are non-IFRS measure with no standardized meaning under IFRS. See the Company’s latest MD&A

for definition and reconciliation to IFRS.

Investment Thesis

OGI INVESTORS’ PRESENTATION |

APPENDIX

OGI INVESTORS’ PRESENTATION | 25

Select Key Financial and Operating Metrics

1. Excludes noncash share based compensation 2. Adjusted EBITDA, adjusted EBITDA as a % of net revenue, all-in and cash cost of cultivation are non-IFRS measures- please see Company’s Q2 2020 MD&A for definition and

reconciliation to IFRS.

(in 000s) unless otherwise indicated Q2-2020 Q2-2019 % Change

Select Key Financial Metrics

Gross revenue 27,309 33,473 -18%

Excise taxes (4,088) (6,539) -37%

Net revenue 23,221 26,934 -14%

Cost of sales 15,811 10,890 45%

Gross Margin (GM) before fair value changes to biological assets & inventories 7,410 16,044 -54%

Fair value changes to biological assets & inventories 3,878 (8,086) -148%

Gross margin 11,288 7,958 42%

Sales & marketing and general & administrative (SG&A)1 14,018 5,741 144%

Net income (loss) from continuing ops (6,833) (6,386) 7%

GM before fair value changes to biological assets & inventories as % of net revenue 32% 60% -28%

SG&A as a % of net revenue 60% 21% 39%

Adjusted EBITDA2 (1,098) 13,256 -108%

Adjusted EBITDA as a % of net revenue2 nm 49% nm

Cash cost of cultivation per gram harvested3 0.53 0.61 -13%

"All-in" cost of cultivation per gram harvested3 0.75 0.87 -14%

Kilograms harvested 13,711 8,315 65%

Kilograms sold 4,093 4,247 -4%

OGI INVESTORS’ PRESENTATION | 26

Select Key Balance Sheet Metrics

Select Balance Sheet Metrics (in 000s) February 29, 2020 August 31, 2019 % Change

Cash and short-term investments 41,239 47,935 -14%

Biological assets and inventories 140,831 113,796 24%

Other current assets 26,264 34,550 -24%

Accounts payable and other current liabilities **

111,582 43,864 154%

Working capital ** 96,752 152,417 -37%

Property, plant and equipment 279,109 218,470 28%

Long-term debt ** 295 46,067 -99%

Total assets 502,276 428,525 17%

Total liabilities 124,175 101,519 22%

Shareholders’ equity 378,101 327,006 16%

** In accordance with IFRS, the Company has classified the long-term portion of the BMO term loan ($76.4 million) to current liabilities as the

Company was in violation of one of the financial covenants contained in the agreement governing the term loan. The Company obtained a waiver

from its lenders that waives compliance with this covenant until May 30, 2020. See “Liquidity and Capital Resources” section in this press release.

27

(in 000s) unless indicated FISCAL 2019 FISCAL 2018 % CHANGE

Gross revenue 97,547 12,429 685%

Excise taxes (17,134) - n/m

Net revenue 80,413 12,429 547%

Cost of sales (incl. indirect production) 42,521 6,814 524%

Gross margin (GM) before FV changes 37,892 5,615 575%

FV changes to bio assets & inventories 10,577 46,018 (77)%

Gross margin 48,469 51,633 (6)%

SG&A1

33,218 10,989 202%

Net income (loss) from continuing ops (9,504) 22, 124 n/m

Select Non-IFRS Metrics

GM before FV changes as % of net revenue 47% 45% 2%

SG&A as a % of net revenue 41% 88% (47)%

Adjusted EBITDA2

19,900 (1,003) n/m

Adjusted EBITDA as a % of net revenue2

25% n/m n/m

Select Key Fiscal 2019 Financial Metrics

1. Sales and marketing and general and administrative expenses (excludes noncash share based compensation and impairment loss)

2. Adjusted EBITDA is a nonIFRS measure –please see Company’s Q4 2019 MD&A.

28

(in 000s) FISCAL 2019 FISCAL 2018 % CHANGE

Cash & Short-Term Investments 47,935 130,064 (63%)

Biological Assets & Inventories 113,796 64,827 76%

Other Current Assets 34,550 8,323 315%

Accounts Payable and Other Current Liabilities 43,864 11,250 290%

Working Capital 152,417 191,964 (21)%

Property, Plant & Equipment 218,470 98,639 122%

Long-Term Debt 46,067 98,473 (53)%

Total Assets 428,525 302,567 42%

Total Liabilities 101,519 117,973 (14)%

Shareholders’ Equity 327,006 184,594 77%

Select Key Fiscal 2019 Balance Sheet Metrics